Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma

A. Kessinger, A. Nademanee, S. J. Forman, James Olen Armitage

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.

Original languageEnglish (US)
Pages (from-to)577-587
Number of pages11
JournalHematology/Oncology Clinics of North America
Volume4
Issue number3
StatePublished - Jan 1 1990

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Hodgkin Disease
Non-Hodgkin's Lymphoma
Graft vs Host Disease
Disease-Free Survival
Lymphoma
Therapeutics
Transplantation
Tissue Donors
Morbidity
Mortality

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. / Kessinger, A.; Nademanee, A.; Forman, S. J.; Armitage, James Olen.

In: Hematology/Oncology Clinics of North America, Vol. 4, No. 3, 01.01.1990, p. 577-587.

Research output: Contribution to journalArticle

@article{6bcaf692e7534ef6a0e89976b8dc8018,
title = "Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma",
abstract = "Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.",
author = "A. Kessinger and A. Nademanee and Forman, {S. J.} and Armitage, {James Olen}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "577--587",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma

AU - Kessinger, A.

AU - Nademanee, A.

AU - Forman, S. J.

AU - Armitage, James Olen

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.

AB - Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.

UR - http://www.scopus.com/inward/record.url?scp=0025356464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025356464&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 577

EP - 587

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -